Pharmaceuticals South Africa

South Africa RSV Vaccines Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

South Africa RSV Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

South Africa · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $24.2 Mn Placeholder estimate
Estimate 2025 $27.5 Mn 0.6% of the global market
Projected 2034 $84.5 Mn 207.7% Adds $57.0 Mn over 9 forecast years
CAGR 2025–2034 13.3% Faster than 67% of 180 Pharmaceuticals markets here
Key players 5
  • South Africa is 0.63% of the global market.
  • In Africa, the largest is South Africa (this report) at $27.5 Mn.
  • Fastest growing: Egypt at 13.9% a year.
  • South Africa ranks 1st of 3 by size in Africa.

Market size projection

South Africa

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$57.0 Mn total, 2026–2034

Year-by-year market size, 2024–2034
RSV Vaccines Market market size by year, South Africa
YearMarket sizeChange that yearSince 2025
2024 (estimate) $24.2 Mn — —
2025 (base) $27.5 Mn +$3.2 Mn —
2026 (forecast) $31.1 Mn +$3.7 Mn +13.3%
2027 (forecast) $35.3 Mn +$4.1 Mn +28.4%
2028 (forecast) $40.0 Mn +$4.7 Mn +45.4%
2029 (forecast) $45.3 Mn +$5.3 Mn +64.8%
2030 (forecast) $51.3 Mn +$6.0 Mn +86.7%
2031 (forecast) $58.1 Mn +$6.8 Mn +111.5%
2032 (forecast) $65.8 Mn +$7.7 Mn +139.7%
2033 (forecast) $74.6 Mn +$8.8 Mn +171.5%
2034 (forecast) $84.5 Mn +$9.9 Mn +207.7%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

South Africa RSV Vaccines Market Analysis at a glance
Market size, 2025$27.5 Mn placeholder estimate
Forecast, 2034$84.5 Mn placeholder estimate
Growth (CAGR), 2025–203413.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, age and end user (see all)
Key playersGSK PLC, Pfizer Inc., Moderna, Sanofi, AstraZeneca (see all)
Regulator in South AfricaSAHPRASource: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
Active clinical trials4 in South AfricaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The South Africa RSV Vaccines Market Analysis Executive Summary

RSV vaccines protect older adults, pregnant women (for their babies) and infants against respiratory syncytial virus, a common cause of serious chest infections.

Key segments of the RSV Vaccines market include product (Older Adult Vaccines, Maternal Vaccines and Infant Monoclonal Antibodies) and age (Infants, Older Adults and Pregnant Women).

Bar chart: South Africa RSV Vaccines market size, 2024–2034, placeholder estimates. $24.2 Mn in 2024, $27.5 Mn in 2025 and $84.5 Mn in 2034, 13.3% CAGR.
South Africa RSV Vaccines market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

South Africa RSV Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the RSV Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the RSV Vaccines market.

Competitive Landscape for RSV Vaccines Market in South Africa

The RSV Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for RSV Vaccines Market in South Africa

RSV Vaccines in South Africa: rules, payment and research

The South African Health Products Regulatory Authority (SAHPRA) registers medicines.⁠[1] Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone.⁠[2] ClinicalTrials.gov lists 4 studies on RSV Vaccines that are recruiting, active or about to start in South Africa.⁠[3]

[1] South African Health Products Regulatory Authority. Checked 14 Nov 2026.

[2] National Department of Health. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for RSV Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in South Africa.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in RSV Vaccines right now, from free public sources.

Clinical trials

4 active trials in South Africa

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Pfizer Inc. 14 active trials on ClinicalTrials.gov (opens in a new tab)
  2. GSK PLC 6 active trials on ClinicalTrials.gov (opens in a new tab)
  3. Sanofi 5 active trials on ClinicalTrials.gov (opens in a new tab)
  4. Guangzhou Patronus Biotech Co., Ltd. 4 active trials on ClinicalTrials.gov (opens in a new tab)
  5. MAXVAX Biotechnology Limited Liability Company 4 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

RSV Vaccines in context

South Africa compared

  • Health spending per person: 537 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 17 countries we cover in Africa.[1]
  • Doctors: 0.79 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 17 countries we cover in Africa.[2]
  • People aged 65 and over: 6.9% of people (2025). World: 10.4% of people (2025). 2nd highest of the 17 countries we cover in Africa.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 18 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 19 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the RSV Vaccines market in South Africa?
Placeholder estimate: about $27.5 Mn in 2025, rising to about $84.5 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the RSV Vaccines market in South Africa growing?
Placeholder estimate: about 13.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the RSV Vaccines market report cover?
The report splits the market by product (Older Adult Vaccines, Maternal Vaccines, Infant Monoclonal Antibodies), age (Infants, Older Adults, Pregnant Women) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the RSV Vaccines market?
Key players include GSK PLC, Pfizer Inc., Moderna, Sanofi and AstraZeneca.
What is driving the RSV Vaccines market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the RSV Vaccines market.
Who regulates RSV Vaccines in South Africa?
The South African Health Products Regulatory Authority (SAHPRA) registers medicines. Source: South African Health Products Regulatory Authority. Checked 14 Nov 2026.
How is healthcare paid for in South Africa?
Most people use public health services and a minority belong to private medical schemes; the National Health Insurance Act, signed in May 2024, plans to fund care for everyone. Source: National Department of Health. Checked 14 Nov 2026.
How many clinical trials on RSV Vaccines are running in South Africa?
4 studies are recruiting, active or about to start in South Africa, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in South Africa. Retrieved 12 Nov 2026.
How much research is published on RSV Vaccines?
PubMed lists 397 papers on RSV Vaccines added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in South Africa

See all

Related on vaccines and respiratory

See the topic